195 related articles for article (PubMed ID: 15273118)
1. Inhibitors of Leishmania mexicana CRK3 cyclin-dependent kinase: chemical library screen and antileishmanial activity.
Grant KM; Dunion MH; Yardley V; Skaltsounis AL; Marko D; Eisenbrand G; Croft SL; Meijer L; Mottram JC
Antimicrob Agents Chemother; 2004 Aug; 48(8):3033-42. PubMed ID: 15273118
[TBL] [Abstract][Full Text] [Related]
2. The CRK3 protein kinase is essential for cell cycle progression of Leishmania mexicana.
Hassan P; Fergusson D; Grant KM; Mottram JC
Mol Biochem Parasitol; 2001 Apr; 113(2):189-98. PubMed ID: 11295173
[TBL] [Abstract][Full Text] [Related]
3. 6-Br-5methylindirubin-3'oxime (5-Me-6-BIO) targeting the leishmanial glycogen synthase kinase-3 (GSK-3) short form affects cell-cycle progression and induces apoptosis-like death: exploitation of GSK-3 for treating leishmaniasis.
Xingi E; Smirlis D; Myrianthopoulos V; Magiatis P; Grant KM; Meijer L; Mikros E; Skaltsounis AL; Soteriadou K
Int J Parasitol; 2009 Oct; 39(12):1289-303. PubMed ID: 19445946
[TBL] [Abstract][Full Text] [Related]
4. High throughput screens yield small molecule inhibitors of Leishmania CRK3:CYC6 cyclin-dependent kinase.
Walker RG; Thomson G; Malone K; Nowicki MW; Brown E; Blake DG; Turner NJ; Walkinshaw MD; Grant KM; Mottram JC
PLoS Negl Trop Dis; 2011 Apr; 5(4):e1033. PubMed ID: 21483720
[TBL] [Abstract][Full Text] [Related]
5. The crk3 gene of Leishmania mexicana encodes a stage-regulated cdc2-related histone H1 kinase that associates with p12.
Grant KM; Hassan P; Anderson JS; Mottram JC
J Biol Chem; 1998 Apr; 273(17):10153-9. PubMed ID: 9553063
[TBL] [Abstract][Full Text] [Related]
6. Recombinant Leishmania mexicana CRK3:CYCA has protein kinase activity in the absence of phosphorylation on the T-loop residue Thr178.
Gomes FC; Ali NO; Brown E; Walker RG; Grant KM; Mottram JC
Mol Biochem Parasitol; 2010 Jun; 171(2):89-96. PubMed ID: 20338198
[TBL] [Abstract][Full Text] [Related]
7. 2,6,9-Trisubstituted purines as CRK3 kinase inhibitors with antileishmanial activity in vitro.
Řezníčková E; Popa A; Gucký T; Zatloukal M; Havlíček L; Bazgier V; Berka K; Jorda R; Popa I; Nasereddin A; Jaffe CL; Kryštof V; Strnad M
Bioorg Med Chem Lett; 2015 Jun; 25(11):2298-301. PubMed ID: 25937014
[TBL] [Abstract][Full Text] [Related]
8. Conditional gene deletion with DiCre demonstrates an essential role for CRK3 in Leishmania mexicana cell cycle regulation.
Duncan SM; Myburgh E; Philipon C; Brown E; Meissner M; Brewer J; Mottram JC
Mol Microbiol; 2016 Jun; 100(6):931-44. PubMed ID: 26991545
[TBL] [Abstract][Full Text] [Related]
9. Stage-specific activity of the Leishmania major CRK3 kinase and functional rescue of a Schizosaccharomyces pombe cdc2 mutant.
Wang Y; Dimitrov K; Garrity LK; Sazer S; Beverley SM
Mol Biochem Parasitol; 1998 Oct; 96(1-2):139-50. PubMed ID: 9851613
[TBL] [Abstract][Full Text] [Related]
10. Identification of inhibitors of the Leishmania cdc2-related protein kinase CRK3.
Cleghorn LA; Woodland A; Collie IT; Torrie LS; Norcross N; Luksch T; Mpamhanga C; Walker RG; Mottram JC; Brenk R; Frearson JA; Gilbert IH; Wyatt PG
ChemMedChem; 2011 Dec; 6(12):2214-24. PubMed ID: 21913331
[TBL] [Abstract][Full Text] [Related]
11. Novel fragment-based QSAR modeling and combinatorial design of pyrazole-derived CRK3 inhibitors as potent antileishmanials.
Goyal S; Dhanjal JK; Tyagi C; Goyal M; Grover A
Chem Biol Drug Des; 2014 Jul; 84(1):54-62. PubMed ID: 24447365
[TBL] [Abstract][Full Text] [Related]
12. Activity of hydroxyurea against Leishmania mexicana.
Martinez-Rojano H; Mancilla-Ramirez J; Quiñonez-Diaz L; Galindo-Sevilla N
Antimicrob Agents Chemother; 2008 Oct; 52(10):3642-7. PubMed ID: 18694950
[TBL] [Abstract][Full Text] [Related]
13. Leishmania mexicana: expression; characterization and activity assessment of E. coli-expressed recombinant CRK3.
Ali NO; Ibrahim ME; Grant KM; Mottram JC
Eur Rev Med Pharmacol Sci; 2012 Oct; 16(10):1338-45. PubMed ID: 23104649
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of the in vitro and in vivo antileishmanial activity of a chloroquinolin derivative against Leishmania species capable of causing tegumentary and visceral leishmaniasis.
Soyer TG; Mendonça DVC; Tavares GSV; Lage DP; Dias DS; Ribeiro PAF; Perin L; Ludolf F; Coelho VTS; Ferreira ACG; Neves PHAS; Matos GF; Chávez-Fumagalli MA; Coimbra ES; Pereira GR; Coelho EAF; Antinarelli LMR
Exp Parasitol; 2019 Apr; 199():30-37. PubMed ID: 30817917
[TBL] [Abstract][Full Text] [Related]
15. An inhibitor-driven study for enhancing the selectivity of indirubin derivatives towards leishmanial Glycogen Synthase Kinase-3 over leishmanial cdc2-related protein kinase 3.
Efstathiou A; Gaboriaud-Kolar N; Smirlis D; Myrianthopoulos V; Vougogiannopoulou K; Alexandratos A; Kritsanida M; Mikros E; Soteriadou K; Skaltsounis AL
Parasit Vectors; 2014 May; 7():234. PubMed ID: 24886176
[TBL] [Abstract][Full Text] [Related]
16. In vitro activity of new N-benzyl-1H-benzimidazol-2-amine derivatives against cutaneous, mucocutaneous and visceral Leishmania species.
Nieto-Meneses R; Castillo R; Hernández-Campos A; Maldonado-Rangel A; Matius-Ruiz JB; Trejo-Soto PJ; Nogueda-Torres B; Dea-Ayuela MA; Bolás-Fernández F; Méndez-Cuesta C; Yépez-Mulia L
Exp Parasitol; 2018 Jan; 184():82-89. PubMed ID: 29191699
[TBL] [Abstract][Full Text] [Related]
17. In vitro and in vivo antileishmanial activity of 2-amino-4,6-dimethylpyridine derivatives against Leishmania mexicana.
Abdala H; Alvarez N; Delmas F; Di Giorgio C; Robert JM; Le Baut G; Le Pape P
Parasite; 2002 Dec; 9(4):367-70. PubMed ID: 12514953
[TBL] [Abstract][Full Text] [Related]
18. Evidence for CRK3 participation in the cell division cycle of Trypanosoma cruzi.
Santori MI; Laría S; Gómez EB; Espinosa I; Galanti N; Téllez-Iñón MT
Mol Biochem Parasitol; 2002 May; 121(2):225-32. PubMed ID: 12034456
[TBL] [Abstract][Full Text] [Related]
19. Activity of Chitosan and Its Derivatives against Leishmania major and Leishmania mexicana
Riezk A; Raynes JG; Yardley V; Murdan S; Croft SL
Antimicrob Agents Chemother; 2020 Feb; 64(3):. PubMed ID: 31871082
[TBL] [Abstract][Full Text] [Related]
20. Effect of DODAB Nano-Sized Cationic Bilayer Fragments against
Ferreira TCS; Sauter IP; Borda-Samper L; Bentivoglio E; DaMata JP; Taniwaki NN; Orrego PR; Araya JE; Lincopan N; Cortez M
Molecules; 2020 Dec; 25(23):. PubMed ID: 33291367
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
